Q
Quantapore
Biotech company developing nanopore-based nucleic acid sequencing technology
About Quantapore
Quantapore is an innovative startup focused on revolutionizing the fields of proteomics and genomics. The company is developing advanced analytical tools that can analyze proteins at the single-molecule level. These tools are designed to work in a massively parallel manner, meaning they can analyze many molecules simultaneously. This technology has the potential to significantly improve human health by providing more detailed and accurate information about proteins, which are essential for understanding diseases and developing new treatments.
Quantapore primarily serves clients in the biotechnology, pharmaceutical, and healthcare sectors. These clients include research institutions, pharmaceutical companies, and healthcare providers who need advanced tools for protein analysis to drive their research and development efforts.
The market Quantapore operates in is the life sciences sector, specifically focusing on proteomics (the study of proteins) and genomics (the study of genes). This market is rapidly growing due to increasing demand for personalized medicine, new drug development, and advanced diagnostic tools.
Quantapore's business model is based on developing and selling its proprietary protein analysis tools. The company generates revenue by selling these tools to its clients and possibly through service contracts for ongoing support and maintenance. Additionally, Quantapore may engage in partnerships or collaborations with other companies and research institutions to further develop and commercialize its technology.
In summary, Quantapore is at the forefront of developing cutting-edge protein analysis tools that have the potential to transform the life sciences industry. By serving clients in biotechnology, pharmaceuticals, and healthcare, the company is well-positioned to capitalize on the growing demand for advanced proteomics and genomics solutions.
Source: Dealroom company dataAt a glance
- Status
- Operational
- Founded
- 2009
- Headquarters
- South San Francisco, United States
- Employees
- 17
- Open positions
- None listed
- Dealroom signal
- 23.7/100
- Industry
- Health
- Sub-industry
- BioTechnology
- Sector
- Biotech & Life Sciences, Biotechnology, DNA, Genetics and genomics, Genome Engineering, Biotech and Pharma, Hard Tech, proteomics, DT and LS, science-based
- Technology
- Deep Tech
- Client focus
- b2b
- Links
- Website
Knowledge graph
More headlines
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| SERIES COther financing | Jul 2018 | $16M | $62M | Baidu Ventures · NLVC | — |
| SERIES COther financing | Sep 2016 | — | — | Baidu Ventures | — |
Growth signals
Latest recorded traffic for Quantapore is 210 monthly website visits, down 61.8% over the last three months. Quantapore's team grew 0% over the past year.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series B and later2 investors entered at this stage
Baidu Ventures
NLVC
Source: Dealroom Talent Intelligence.
Global footprint
Market sentiment
An AI-synthesised read of the highest-engagement posts about Quantapore on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Quantapore’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.